ABSTRACT
MATERIALS AND METHODS
Cells. The human neuroblastoma cell line SH-EP was cultured in RPMI 1640 medium (Life Technologies, Eggenstein, Germany) supplemented with 10% heat-inactivated FCS (Biochrom, Berlin), 10 mM of Hepes, pH 7.3 (Biochrom), 100 units͞ml of penicillin, 100 g͞ml of streptomycin (both from Life Technologies), and 2 mM of L-glutamine (Biochrom).
Generation of TK Retroviral Vector. The retroviral vector tgLs(ϩ)HyTK, which contains a hygromycin phosphotransferase-TK fusion gene driven by the long terminal repeat promoter (4), was employed.
Transduction and Transfection of Cells. The TK gene was transduced as described (5) . Bulk cultures (SH-EP pHyTK) were expanded and subcloned. In addition, SH-EP cells were transfected with the control vector pLXSN (6) (SH-EP pLXSN), by using calcium phosphate precipitation according to instructions of the manufacturer (Stratagene). pcDNA3 containing FADD, with the death effector domain deleted [clone NFD4 (7) ], was electroporated into SH-EP pHyTK, and transfectants were subcloned (SH-EP pHyTK͞FADD). As a control, a SHEP pHyTK subclone was electroporated with pcDNA3 lacking an insert (SH-EP pHyTK͞pcDNA).
Measurement of Apoptosis. DNA fragmentation was measured by flow cytometric analysis of propidium iodide-stained nuclei as described (8) . The percentage of specific apoptosis was calculated as follows: [experimental apoptosis (%) Ϫ spontaneous apoptosis in medium (%)]͞[100% Ϫ spontaneous apoptosis in medium (%)] ϫ 100.
Immunoblot Analysis. Immunoblot analysis was performed as described (9) with minor modifications. Membranes were incubated with primary and secondary antibodies for 1 h each and developed with enhanced chemiluminescence (Amersham Pharmacia). The following mouse mAbs were used: anti-FLICE C15 [1:10 dilution of hybridoma supernatant (10) ], anti-FADD (1:1,000; Transduction Laboratories, Lexington, KY), anti-CPP32 (1:1,000; Transduction Laboratories), antip53 (1:1,000; Transduction Laboratories), anti-CD95 (1:500; Transduction Laboratories), anti-␤-Actin (1:5,000; Sigma), and anti-␣-tubulin (1:3,000; Calbiochem). Rabbit polyclonal antibodies were employed for the detection of TK (1:300) and poly(ADP-ribose) polymerase (PARP) (1:5,000; Boehringer Mannheim). Goat anti-mouse and anti-rabbit IgGs were used as secondary antibodies (1:5,000; Santa Cruz Biotechnology).
Inhibition with zVAD-fmk and zIETD-fmk. Cells (2 ϫ 10 4 per well) were treated with 10 M of GCV (Hoffmann-La Roche). Broad-range tripeptide caspase inhibitor zVAD-fmk (50 M; Bachem) was used, with an additional 30 M of zVAD-fmk added after 36 h. zIETD-fmk (100 M; Calbiochem) was employed with a medium change containing the same zIETD-fmk concentration after 24 h. Specific apoptosis was determined after 72 h.
Assessment of FADD Dependency by a Dominant Negative FADD Mutation. Randomly chosen SH-EP pHyTK͞FADD clones were treated in individual experiments with 2 M of staurosporine (Sigma) for 12 h, 1 g͞ml of anti-APO-1͞5 ng/ml of protein A͞2 g/ml of cycloheximide for 24 h, or 10 g͞ml of GCV for 72 h. Apoptosis was measured and compared with identically treated SH-EP pHyTK subclones and SH-EP pHyTK͞pcDNA. Clonogenicity was determined after treating cells with 10 M of GCV for 9 days by replating 500 cells per well in 24-well plates. Colonies were counted after 4 days.
Reverse Transcription-PCR. Total RNA was extracted by using the RNeasy kit (Qiagen). Reverse transcription-PCR of CD95-L, TNF-␣, and TNF-related apoptosis-inducing ligand (TRAIL) was performed with primers described previously (3, 11) . Primer for the TR A IL receptor DR5 were 5Ј-GAGAGCGGCCCCACAACAAAAGA-3Ј and 5Ј-CCT-GGGTGGGCTGCAAGATACTCA-3Ј. ␤-Actin primer was used for controls (MWG-Biotech, Ebersberg, Germany). The Gene Amplification RNA-PCR kit (Perkin-Elmer) was used according to the manufacturer's instructions with the following modifications: annealing temperature and cycle number for CD95-L were 57°C and 40; for TNF-␣, 58°C and 34; for DR5, 56C°and 27; and for ␤-actin, 58C°and 28; respectively. PCR products were analyzed by using 1.5-2.0% agarose gels stained with ethidium bromide.
Blockage of Death Receptors and Death Ligands. SH-EP pHyTK11 cells were treated in individual experiments with 0.1 g͞ml of anti-APO-1 (12) with or without 25 g͞ml of the blocking F(abЈ) 2 anti-APO-1 (13), 1 ng͞ml of recombinant human TNF-␣ (Calbiochem) in the presence or absence of 25 g͞ml of anti-TNF-␣ (Sigma), and 10 M of GCV with or without F(abЈ) 2 anti-APO-1, and anti-TNF-␣, respectively.
Measurement of TK͞GCV-Mediated Sensitization to Death Ligands. Cells were treated with 10 M of GCV for 24 h followed by incubation without GCV for an additional 24 h in the presence or absence of either 0.1 g anti-APO-1 with 5 ng͞ml of protein A, 100 ng͞ml of TNF-␣, 1:30 dilution of TRAIL hybridoma supernatant, or 0.001 M staurosporine. Apoptosis was measured and compared with cells treated for 24 h (12 h for staurosporine) with the same inducers in identical concentrations but without prior GCV treatment.
Assessment of CD95 Aggregation by Limiting Antibody Conditions. Cells were treated with 10 M of GCV for 36 h. CD95 crosslinking and immunoprecipitation was performed as described (14) with the following modifications: CD95 was immunoprecipitated by using anti-APO-1 antibody at a limiting concentration of 0.5 g͞ml and at excess concentration of 2.0 g͞ml. After precipitation with protein A-Sepharose, the precipitate was resolved by SDS͞PAGE and electroblotted to a nitrocellulose membrane (Amersham). CD95, FADD, and caspase-8 were detected by immunoblot, using the appropriate primary and secondary antibodies as detailed above.
Determination of Death Receptor Expression. CD95 and TNF receptor 1 (TNF-R1) expression was detected by flow cytometry as described previously (9), using mouse anti-APO-1 and anti-TNF-R1 mAbs (Boehringer Ingelheim) followed by goat anti-mouse IgG-phycoerythrin (Immunotech, Luminy, France).
Golgi Blockade. This was performed by blocking the Golgi with 1 g͞ml of brefeldin A (Sigma) for 24 h.
RESULTS
Kinetic and Dose Response of TK͞GCV-Induced Apoptosis. SH-EP pHyTK bulk cultures as well as the selected clone SH-EP pHyTk11 were equally killed effectively by GCV, depending on time and GCV dose, with minimal unspecific toxicity, as shown by SH-EP pLXSN cells, which did not contain TK (data not shown). Therefore, both SH-EP pHyTK bulk cultures and SH-EP pHyTK11 were used interchangeably in subsequent experiments, in which GCV concentrations of 2 and 10 M were employed.
TK͞GCV-Induced Apoptosis Involves Activation of Caspases. To delineate the effector pathways of TK͞GCV-induced apoptosis, we first examined the role of caspases, central effectors of apoptosis, to which various known, deathinducing signaling pathways converge. In TK-containing cells but not in cells lacking TK, the caspase cascade became activated after GCV treatment ( after administration of GCV, coinciding with the onset of apoptosis. Consecutively, PARP was almost completely cleaved at 96-120 h. Similar results were obtained with bulk cultures. To determine whether caspase activation is necessary for TK͞GCV-mediated apoptosis, we blocked the caspase pathway by the broad-range caspase inhibitor zVAD-fmk. As shown in Fig. 1B , both DNA fragmentation, as measured by enumerating hypodiploid nuclei, and cell membrane permeability, as determined by trypan blue uptake, were inhibited markedly, indicating the importance of caspase activation for TK͞GCV-induced apoptosis and cell death. However, inhibition was not complete and decreased at 96 h (data not shown), suggesting that either caspase-independent cell death mechanisms were utilized at later time points or that blockage of caspases by zVAD-fmk was incomplete. Similar results were obtained with SH-EP pHyTK bulk cultures (data not shown). TK͞GCV Induces Expression of TRAIL but Not of CD95-L and TNF. We then searched for triggers activating the caspase cascade. Some cytotoxic drugs have been shown to increase expression of CD95-L and CD95, which may contribute to killing under certain conditions (3, 9) . Therefore, it was conceivable that TK͞GCV-mediated apoptosis may proceed through such an autocrine loop. We hence determined the induction of death-inducing ligands by TK͞GCV. Although TRAIL mRNA was induced, TNF mRNA did not increase above the constitutive mRNA level, and no constitutive or induced CD95-L mRNA was detectable ( Fig. 2A) . Low-level expression of CD95-L protein was detected by Western blot (data not shown).
TK͞GCV-Mediated Apoptosis Is Not Blocked by Antibodies Against CD95 and TNF. To define further the role of CD95-L and TNF, we blocked CD95 and TNF signaling by antagonistic antibodies. Both F(abЈ) 2 anti-APO-1 and anti-TNF-␣ effectively blocked apoptosis induced by the respective ligands but not TK͞GCV-mediated apoptosis (Fig. 2B) .
TK͞GCV Induces p53, Up-Regulates Death Receptors Likely Involving p53-Mediated Translocation of CD95, and Sensitizes to Death-Inducing Ligands. Accumulation of wildtype p53 protein has been found in response to DNA damage. Cytotoxic drugs may up-regulate CD95 expression by increased transcription mediated by p53 (9, 15, 16) . Recently, p53-dependent translocation of preformed CD95 from the Golgi apparatus to the cell surface independent of increased transcription has been described (17) . We therefore reasoned that TK͞GCV may act similarly. TK͞GCV, indeed, did induce p53, starting 12 h after TK͞GCV, without de novo synthesis of CD95 protein (Fig. 3A) but associated with increased cell surface expression of CD95 and TNF-R1 (Fig. 3B) . Disruption of the Golgi by brefeldin A prevented CD95 translocation (Fig.  3B) , suggesting that TK͞GCV induces p53-mediated translocation of CD95. Given the up-regulation of death receptors, we reasoned that TK͞GCV-treated cells may become more susceptible to death induced by their cognate ligands. Apoptosis by anti-APO-1 and TNF-␣ (Fig. 3C) as well as by TRAIL (data not shown) was enhanced synergistically by TK͞GCV, suggesting that TK͞GCV sensitizes target cells for apoptosis by death-inducing ligands. TK͞GCV also sensitized to low-dose staurosporine, suggesting that, in addition to up-regulation of death receptors, sensitization also occurred downstream of death receptors (data not shown).
TK͞GCV-Induced Apoptosis Involves Brefeldin A-Inhibitable Aggregation of CD95, Causing DISC Formation. We next wanted to know whether TK͞GCV influences the CD95 pathway despite the apparent absence of CD95͞CD95-L interaction. Because we found that TK͞GCV up-regulates CD95 we asked whether CD95 aggregation and signaling may occur in the absence of CD95͞CD95-L interaction. To address this question, we examined CD95 aggregation by immunoprecipitating CD95, using limiting antibody concentrations. Under these conditions CD95 is precipitated significantly only when receptors are crosslinked. Without aggregation of CD95, the few antibody molecules will bind to single receptors only, resulting in unappreciable amounts of precipitated CD95 (18) . Indeed, using a limiting anti-CD95 concentration, crosslinked CD95 was detected in TKϩ but not in TKϪ cells upon GCV treatment, whereas with excess antibody, non-cross-linked receptors were detected in TKϪ cells as well (Fig. 4A) . We then wanted to know whether TK͞GCV-induced CD95 aggregation may initiate the caspase cascade by formation of a DISC after recruitment of FADD and the receptor-proximal caspase-8 to the CD95 receptor. As shown in Fig. 4B , TKtransfected cells recruited both wild-type (WT) and dominant negative (DN) FADD to CD95 after GCV. Caspase-8 was recruited only in cells containing FADD-WT, but not in those with FADD-DN lacking the death effector domain. These results suggest that CD95 receptor aggregation in the absence of CD95-L may trigger the caspase cascade in TK͞GCV therapy. To test whether the observed p53-mediated CD95 translocation has an effect on CD95 signaling, we determined DISC formation after Golgi blockade by using brefeldin A. As shown in Fig. 4C , DISC formation was decreased after Golgi disruption, suggesting that CD95 signaling is facilitated by p53-mediated CD95 translocation after TK͞GCV.
TK͞GCV-Mediated Apoptosis Is Decreased by Inhibition of FADD and Caspase-8. FADD is recruited to death receptors of the TNF receptor family such as CD95, the TNF receptors, and TRAIL-DR5 upon activation and functions as an adapter molecule between these receptors and caspases, e.g., caspase-8 (7, 19) . Therefore, we reasoned that a dominant negative FADD mutation (FADD-DN) would interfere with TK͞GCV-mediated apoptosis. As shown in Fig. 5A , clones transfected with TK and FADD-DN expressed both genes to varying degrees. TK͞GCV-mediated apoptosis was decreased in the FADD mutants depending on the amount of FADD-DN expression (Fig. 5B) . As expected, anti-APO-1-triggered apoptosis was decreased markedly in the presence of high levels of FADD-DN (Fig. 5C ). Two clones with almost complete ablation of FADD function remained clonogenic after prolonged exposure to GCV (Fig. 5D ). To exclude nonspecific effects of FADD-DN we employed the complementary approach of inhibiting the most apical initiator caspase of CD95, TNF-R1, and TRAIL-DR5 signaling, caspase-8. The caspase-8 inhibitor zIETD-fmk decreased TK͞GCV-induced apoptosis, supporting a role of death receptor signaling in TK͞GCV cytotoxicity (Fig. 5E ). All clones and controls underwent apoptosis to the same degree, with 2 M of the protein C kinase inhibitor staurosporine given for 12 h, showing that the apoptosis machinery downstream of FADD was intact in these cells (data not shown).
DISCUSSION
TK͞GCV strongly induced CD95 receptor expression and CD95 receptor aggregation in the absence of CD95-L induction. CD95-L-independent aggregation of CD95 leading to apoptosis has been described for other forms of cellular stress, e.g., UV light (18) . CD95 cell surface expression may be a consequence of p53-dependent transcription (9, 15, 16) or p53-dependent translocation of preformed receptor to the cell surface (17) . TK͞GCV induced p53 concomitant with upregulation, but not induction of CD95 protein. Disrupting the Golgi, which has been shown to block p53-mediated CD95 translocation, inhibited CD95 surface expression, suggesting that TK͞GCV induces p53-mediated translocation of CD95 to the cell surface. The increased surface expression of CD95 may lead to increased interaction with CD95-L constitutively expressed on the cell surface or, alternatively, may contribute to CD95 self-aggregation by crowding of the receptor. Overexpression of FADD has been shown to trigger apoptosis independent of CD95 (7). However, TK͞GCV did not increase FADD expression (data not shown). TK͞GCV activates the CD95 as shown by the recruitment of FADD and caspase-8, thus triggering the caspase cascade. Initiation of CD95 signaling is inhibited when CD95 translocation is blocked, showing that TK͞GCV-induced CD95 translocation contributes to initiate the CD95-signaling cascade.
In addition to CD95, both BAX and TRAIL-DR5 are transcriptional targets of p53 in response to genotoxic stress (20, 21) . However, BAX protein and TRAIL-DR5 mRNA were not up-regulated after TK͞GCV (data not shown). We have not ruled out translocation of BAX from the cytosol to the mitochondria or of TRAIL-DR5 from the Golgi to the cell surface in response to TK͞GCV. TK͞GCV has been shown to arrest tumor cells in late S͞G 2 phase by p53-dependent induction of p21 CIP1͞WAF1 (22) . Thus, besides mediating apoptosis, TK͞GCV-induced p53 accumulation contributes to tumor 
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Medical Sciences: Beltinger et al. Proc. Natl. Acad. Sci. USA 96 (1999) control by inhibiting proliferation. Finally, p53 is known to induce genes related to the redox state, the formation of reactive oxygen species, and the oxidative degradation of mitochondrial components (23) . Therefore, the role of mitochondria in TK͞GCV-induced apoptosis warrants further investigation. Besides CD95 activation, TK͞GCV primes the CD95 pathway as shown by sensitization to triggering by the agonistic antibody anti-APO-1. This sensitization may be explained by the up-regulation of the receptor. However, sensitization also may involve downstream elements of the apoptotic pathway (e.g., mitochondrial activation) because staurosporineinduced apoptosis, which acts distal of death receptors, was found to be increased.
It is conceivable that TRAIL-receptor, whose ligand was selectively up-regulated among the death-inducing ligands after TK͞GCV, may activate DR4͞5 and, thus, trigger apoptosis. Therefore, the role of DR4͞5 requires further analysis. In contrast, TNF was not up-regulated, nor did blockage of it decrease apoptosis after TK͞GCV, suggesting no role of TNF in this process.
TK͞GCV-mediated apoptosis is at least partially FADDdependent, because only clones strongly expressing FADD-DN were protected from TK͞GCV-mediated apoptosis and remained clonogenic after long-term exposure to GCV. This indicates that the FADD-dependent pathway of TK͞ GCV-mediated apoptosis was nonredundant in these clones with regard to ablation of clonogenic potential, even after prolonged GCV exposure. This implies that death receptordriven signaling pathways play a role in TK͞GCV-mediated apoptosis. Because we have demonstrated activation of CD95, this receptor is likely to be involved in TK͞GCV-induced apoptosis. However, this does not exclude a role for other death receptors such as DR5. Other clones with the FADD mutation had lost their clonogenic potential, suggesting either incomplete loss of FADD function or the utilization of FADDindependent cell death pathways by TK-GCV. Recently, several lines of evidence suggested hat FADD, in addition to its role in apoptosis signaling through death receptors, may have a function in proliferative response, e.g., in T cells (24) . Proliferation of FADD mutants was decreased slightly during the culture period (data not shown). Because GCV action depends on proliferation (25) , the decreased proliferation of the FADD mutants may have contributed to their GCV resistance.
The role of death receptor-driven apoptosis in TK͞GCV-mediated cytotoxicity is supported further by the attenuation of apoptosis by the caspase-8 inhibitor zIETD-fmk. This inhibition was not complete, which could imply that apoptosis pathways not driven by death receptors may also be involved. However, the partial inhibition of anti-APO-1-induced apoptosis in zIETD-fmk-treated SH-EP cells (data not shown) suggests incomplete inhibition of caspase-8 by zIETD-fmk. This is in contrast to zVAD-fmk, which almost completely blocked both anti-APO-1 (data not shown) and GCV-induced apoptosis. Therefore, the incomplete inhibition of TK͞GCV-mediated apoptosis by zVAD-fmk suggests that caspaseindependent cell death pathways are triggered by TK͞GCV, at least after prolonged treatment. Recently, it has been shown in some cell lines that the inhibition of caspases causes a switch from caspase-dependent apoptosis to caspase-independent necrosis (26) . However, we did not detect the morphological characteristics of necrosis after inhibiting caspases during TK͞GCV treatment, suggesting that alternative caspaseindependent apoptotic cell death pathways were used. That these pathways became functional after caspases had been blocked suggests that the caspase-dependent pathway is taken as the default route to cell death by TK͞GCV in SH-EP cells. In addition, mechanisms of TK͞GCV-induced cell death may vary between different cell types, because in B16 melanoma cell lines induction of necrosis rather than apoptosis was found after TK͞GCV treatment (22, 27) . The sensitization of TK͞GCV-treated cells for CD95, TNF-R1, and TRAIL-receptor-induced apoptosis may be due to up-regulation of the receptors and downstream sensitization of the respective pathways. Death receptor sensitization may have important implications for the bystander effect, the proximal and distal killing of nontransduced cancer cells (1, 28) . This effect is crucial for the clinical efficacy of suicide gene cancer therapy, given the low in vivo transfection efficiency of currently used vectors. The immunological component of the bystander effect is exerted by CD4 ϩ and CD8 ϩ T cells, natural killer (NK) cells, and macrophages infiltrating TK͞GCV-treated tumors (29) (30) (31) (32) . These cells kill, in part, by deathinducing ligands: the mononuclear infiltrate has been shown to express TNF (30, 31) , cytotoxic T cells can kill both by CD95-L (33) and TRAIL (34) , and NK cells use CD95-L (35) . We therefore propose that TK͞GCV-induced sensitization to these death ligands enhances the bystander effect.
Our findings may provide a starting point to improve the efficacy of suicide gene therapies of cancer by increasing the sensitivity of target and bystander cells through enhancement of apoptosis.
